Owkin: machine learning with privacy protection
Owkin deploys AI solutions using real-world data to optimize drug development while maintaining patient privacy
To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions.
Gilles Wainrib, Owkin’s co-founder and CSO, said that although drug development is often based on the analysis of small data sets from clinical trials, hospitals generate a large amount of real-world data that can be used to optimize drug development.
Hospitals, especially those in the U.S., do not want to share